Is hesperidin alone enough?

The evidence is for the diosmin-hesperidin combination. Hesperidin-only products have not been tested to the same standard.

Will it cure my haemorrhoids?

No. It reduces bleeding and symptoms during flares; established prolapsing haemorrhoids usually need a procedure.

How quickly does bleeding settle?

Trials typically report improvement within the first several days of the high-dose phase.

Condition

Moderate Evidence

Effectiveness 4/5

Hesperidin for Hemorrhoids

Micronised diosmin with hesperidin shortens acute haemorrhoidal episodes — bleeding, pain and swelling resolve faster — and is a guideline-recognised treatment across much of Europe.

Overview

Hesperidin is rarely used alone for haemorrhoids. It appears as roughly ten percent of micronized purified flavonoid fraction (MPFF), the diosmin-hesperidin combination that has been studied in over 1,500 participants and is prescribed for haemorrhoidal disease across much of Europe.

A systematic review and meta-analysis found flavonoid preparations reduced bleeding and persisting symptoms, while noting that the trials were of low methodological quality with possible publication bias. Bleeding is the endpoint that moved most consistently. So the practical claim is symptom control during an acute flare and fewer persisting symptoms afterwards. It does not shrink established haemorrhoids or remove the need for a procedure in advanced disease, and the quality caveats mean the true effect is probably smaller than the pooled figures suggest.

Verdict

Likely effective

Meta-analysis of flavonoid preparations shows reduced bleeding and persisting symptoms in haemorrhoidal disease, tempered by low trial quality and possible publication bias.

How It Works

Haemorrhoidal symptoms come from engorged, inflamed vascular cushions with leaky capillaries and impaired venous return. Hesperidin and diosmin are venotonic flavonoids that raise venous tone and reduce capillary permeability.

They also prolong the vasoconstrictor action of noradrenaline on the vein wall and reduce leukocyte adhesion in the microcirculation, which dampens the local inflammatory component. Together these actions explain reduced bleeding and less swelling during a flare. Micronization matters mechanically rather than pharmacologically: reducing particle size improves absorption of otherwise poorly soluble flavonoids, which is why the trial products are described as micronized.

Active pairing: Diosmin 90% with hesperidin 10% (MPFF)
Primary target: Venous tone and capillary permeability
Secondary effect: Reduced leukocyte adhesion and local inflammation
Best-fit user: Acute haemorrhoidal flare with bleeding
Poor fit: Grade IV prolapse or thrombosed external haemorrhoid

Dosing & Protocol

The standard regimen is front-loaded. Acute flares are treated with 3000 mg of MPFF daily for four days, then 2000 mg for three days, dropping to 1000 mg daily for maintenance.

Context	Dose	Form	Timing
Acute flare, days 1-4	3000 mg daily	MPFF (diosmin-hesperidin) tablets	Split into 2-3 doses with meals
Acute flare, days 5-7	2000 mg daily	MPFF tablets	Two doses with meals
Maintenance	1000 mg daily	MPFF tablets	Once or twice daily
Assessment window	7 days acute; 2-3 months maintenance	MPFF	Daily

1
Get rectal bleeding assessed· Before starting
Never assume bleeding is haemorrhoidal. It requires a clinical diagnosis, particularly over age 45 or with any change in bowel habit.
2
Fix stool consistency first· Ongoing
Fibre to 25-30 g daily and adequate fluid do more for haemorrhoids than any flavonoid.
3
Run the acute taper· Days 1-7
3000 mg for four days, then 2000 mg for three, taken with food.
4
Drop to 1000 mg maintenance· Weeks 2-12
Continue if flares are recurrent; stop if symptoms have settled.
5
Escalate if bleeding persists· After 7 days
Ongoing bleeding past a week of treatment warrants review for banding or another procedure.

Rectal bleeding needs a diagnosis, not a supplement

Colorectal cancer and inflammatory bowel disease both present with rectal bleeding. Get it examined before self-treating, especially if it is new or you are over 45.

Evidence

The linked systematic review and meta-analysis pooled 1,514 participants across flavonoid trials in haemorrhoidal and chronic venous disease. It found reduced bleeding and fewer persisting symptoms, while explicitly flagging low methodological quality and possible publication bias.

Systematic review and meta-analysis linked to this pairing.

Micronized purified flavonoid fraction containing hesperidin and diosmin for haemorrhoidal disease and chronic venous disease: systematic review and meta-analysis

Score: 7/10

2012

systematic_review

n=1514

Perera N, Liolitsa D, Iype S +5 more

Flavonoid preparations reduced bleeding and persisting symptoms in haemorrhoidal disease, but trials were of low methodological quality.

View source

Best available evidence: Systematic review and meta-analysis, n=1514
Typical effect: Reduced bleeding and fewer persisting symptoms
Studied dose: MPFF 1000-3000 mg daily depending on phase
Time to effect: Days for bleeding; weeks for persisting symptoms
Main limitation: Low trial quality and possible publication bias

Safety

MPFF has a long clinical track record in Europe with good tolerability. Mild gastrointestinal upset and occasional headache are the usual complaints, most often during the high-dose acute phase.

Cautions

GI upset and nausea at the 3000 mg acute dose

Occasional headache or dizziness

Limited safety data in pregnancy

Does not replace assessment of unexplained rectal bleeding

Rare skin reactions reported

Interactions & Conflicts

Documented drug interactions are few. The theoretical ones follow from flavonoid effects on drug-metabolising enzymes and on platelet function, neither of which has produced clear clinical problems at these doses.

Interacts with	Severity	Mechanism	Action
Anticoagulants	low	Theoretical mild antiplatelet effect from flavonoids	Mention it to your prescriber; no routine change needed
CYP-metabolised medicines	low	Flavonoids can modestly inhibit some CYP enzymes	Relevant only for narrow-margin drugs; ask a pharmacist
Other venotonics such as horse chestnut	low	Overlapping mechanism without added evidence	Use one at a time
Topical haemorrhoid preparations	low	Different route, complementary action	Safe to combine during a flare

References

Perera N et al. Micronized purified flavonoid fraction for haemorrhoidal disease and chronic venous disease: systematic review and meta-analysis. Cochrane Database Syst Rev. 2012

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.